ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾

English

½ÓÊܶ©»õ£¡ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾ÉúÎXa²â¶¨ÊÔ¼ÁºÐ»ñµÃÒ½ÁÆÆ÷еע²áÖ¤£¡

Ðû²¼ÓÚ£º2023-08-09

ÎÄÕÂȪԴ£º[ÖÐÎÄ]ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾ÉúÎï



¹ÙÐû


ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾ÉúÎXa£¨·¢É«µ×Îï·¨£©Ë³ËìÈ¡µÃ±±¾©ÊÐÒ©Æ·¼àÊÓ¹ÜÀí¾Ö½ÒÏþµÄ¡¶Ò½ÁÆÆ÷еע²áÖ¤¡·¡£




 ¿¹Xa²â¶¨ÊÔ¼ÁºÐ

·¢É«µ×Îï·¨





µã»÷Éó²é´óͼ





ǰÑÔ

ÏÖÔÚ  £¬¾²ÂöѪ˨˨ÈûÐÔ¼²²¡£¨venous thromboembolism, VTE£©ºÍ¶¯ÂöѪ˨˨ÈûÐÔ¼²²¡³ÉΪµ¼ÖÂÈ«ÇòÉú³ÝéæÃüµÄµÚһλԵ¹ÊÔ­ÓÉ¡£´ó´ó¶¼¾²ÂöѪ˨ÓÉÓÚûÓÐÖ¢×´Ò×±»Â©Õï¡¢ÎóÕï  £¬µ«VTEÊÇ¿ÉÒÔÔ¤·ÀµÄ  £¬¿¹Äý¾ÍÊÇÔ¤·ÀºÍÖÎÁƵĻù´¡¡£¿ÉÊÇÔõÑù×èÖ¹¿¹ÄýÖÎÁƵ¼ÖµijöѪÐÔΣº¦  £¬¡¶ÖйúѪ˨ÐÔ·ÀÖÎÖ¸ÄÏ¡·£¨2018£©¹ØÓÚ²î±ð¿¹ÄýÒ©Îï¸ø³öÁËÏà¹ØµÄ¼à²âÖ¸±ê¡£


  • ÈôÓ¦ÓÃUFHÖÎÁÆ  £¬ÍƼöÒ»Á¬¾²Âö¸øÒ©²¢Æ¾Ö¤»î»¯²¿·ÖÄýѪøԭʱ¼ä£¨APTT£©¼à²âЧ¹ûµ÷Àí¼ÁÁ¿  £¬Ö±ÖÁAPTTÑÓÉìÖÁ¿¹ÄýǰµÄ1.5~2.5±¶  £¬»òµÖ´ïÏ൱ÓÚѪ½¬UFHˮƽ0.3~0.7 U/ml ʱµÄ¿¹ XaÒò×Ó£¨FXa£©»îÐÔˮƽ¡¾1C¡¿¡£

  • ÖðÈÕÐè´ó¼ÁÁ¿UFHÖÎÁƶøAPTT²»´ï±êʱ  £¬ÍƼöͨ¹ý¼à²â¿¹FXaµÄˮƽָµ¼ÓÃÒ©¼ÁÁ¿¡¾1B¡¿¡£

  • Ó¦ÓÃLMWHÖÎÁƼ±ÐÔDVTʱ  £¬ÈôºÏ²¢ÑÏÖØÉö¹¦Ð§²»È«£¨¼¡ôûɨ³ýÂÊ<30 ml/minʱ  £¬É÷ÓÃLMWH£©  £¬½¨ÒéLMWH¼õÁ¿²¢¼à²â¿¹FXa»îÐÔ¡¾2C¡¿¡£



¡¶¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÖÎÁÆÖйúר¼Ò¹²Ê¶£¨2015£©¡·¶ÔµÍ·Ö×Ó¸ÎËØµÄÖÎÁƹæÄ£Ò²¸ø³öÁ˽¨Ò飺ÈÑÉïʱ´úÐè°´ÆÚ¼à²â¿¹Xa»îÐÔ  £¬Æä·åÖµÓ¦ÔÚ×î½üÒ»´Î×¢Éäºó4h²â¶¨  £¬¹ÈÖµÓ¦ÔÚÏ´Î×¢Éäǰ²â¶¨  £¬¿¹Xa»îÐÔÄ¿µÄ¹æÄ£Îª0.6¡«1.0 IU£¯ml  £¬ÌìÌì¸øÒ©1´ÎµÄÄ¿µÄ¹æÄ£Îª1.0¡«2.0 IU£¯ml¡£


Ðí¶à»ú¹¹Ê¹Óÿ¹XaÒò×Ó»îÐԲⶨ×÷Ϊ½ð±ê×¼²âÊÔ  £¬ÒÔ¼à²âºÍµ÷½âÖÎÁÆÐÔδ·Ö×é¸ÎËØºÍµÍ·Ö×Ó¸ÎËØÖÎÁƵĹÜÀí¡£

¡ª¡ª¡¶ELSO Anticoagulation Guideline¡·


ÏÔÉ«¿¹XaÒò×ӲⶨÊÇÏÖÔÚ¼à²âµÍ·Ö×Ó¸ÎËØºÍ»Ç´ï¸Î¿ûÄÆÖÎÁƵĽð±ê×¼¡£

¡ª¡ª¡¶Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux¡·


ʹÓÃUFHºÍLMWH¾ÙÐп¹ÄýÖÎÁÆÊ±  £¬ÏÂÁÐÈËȺÐèÒª¾ÙÐмà²â£º

#  Ó¤Ó×¶ùºÍ¶ùͯ

#  ÀÏÈË£¨ÄêËꣾ85Ë꣩

#  ÌåÖØÒì³£Õß

#  ¼¡ôûɨ³ýÂÊÔÚ15¡«30 mL£¯minµÄÂýÐÔÉö²¡Õß

#  ÈÑÉ︾Ů

#  ÓгöѪΣº¦µÄ»¼ÕßµÈ


¿¹Xa»îÐÔ¼ì²â


¼ì²âÔ­ÀíΪ£ºÑù±¾ÖеĸÎËØÓ뿹ÄýѪøÍŽáÐγɸ´ºÏÎïºó  £¬»áÓ벿·ÖXaÍŽá  £¬²¢Ê¹Õⲿ·ÖXaʧ»î¡£Ê£ÓàµÄXa¿É½«ºÏ³ÉµÄÏÔÉ«µ×ÎïÆÊÎö±¬·¢¶ÔÏõ»ù±½°·£¨PNA£©  £¬PNAÔÚ405nm´¦ÓÐ×î´óÎüÊÕ·å  £¬Í¨¹ý²â¶¨¶ÔÏõ»ù±½°·µÄÐγÉÁ¿À´ÅÌËã¸ÎËØ»îÐÔ¡£


¿¹Xa»îÐÔ¼ì²âÔ­Àíͼ



ÊÔ¼ÁÐÔÄÜ


ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©Í¨¹ýÑÕɫת±äÀ´²â¶¨¿¹ÄýÇ¿¶È/ѪҩŨ¶È  £¬ÏßÐÔ¿í  £¬¿¹×ÌÈÅÄÜÁ¦Ç¿  £¬Ï¸Ãܶȸß  £¬ÓëÊг¡Ö÷Á÷³§¼ÒÊÔ¼ÁÏà¹ØÐÔÓÅÒì  £¬R2£¾0.95  £¬¿ÉÖª×ãÁÙ´²¼ì²âÐèÇó¡£


£¨Êý¾ÝȪԴ£º¿¹Xa¶àÖÐÐÄÒ½ÔºÑù±¾±È¶ÔÊý¾Ý£©


½ð˹¶û¿¹XaÊÔ¼Á¿ÉÒÔÖª×ãÁÙ´²Ô¤ÆÚÓÃ;£º

½ð˹¶û¿¹XaÊÔ¼ÁºÐͨË׸ÎËØÏßÐÔ¿ÉÒÔ×öµ½4IU/mL  £¬²»µ«¿ÉÒÔÖª×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL  £¬Í¬Ê±¿ÉÒÔÖª×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÇó¡£


¿¹×ÌÈÅÄÜÁ¦Ç¿£º

ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾¿¹XaÊÔ¼ÁºÐ²¿·ÖÖ¸±ê  £¬¿¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á¡£





С½á

¿¹Xa»îÐÔÊÔÑé¿ÉÓÃÓÚUFH¡¢LMWH¡¢»Ç´ï¸Î¹ïÄÆ¡¢Ö±½ÓFXaÒÖÖÆ¼ÁµÈ¶àÖÖÒ©ÎÄýÇ¿¶È/ѪҩŨ¶ÈµÄ²â¶¨¡£

4¼ÒÈý¼×Ò½ÔºÅäºÏ¼ÓÈëÁËÖйúÑо¿ÐÍҽԺѧ»áµÄ¡°¹ú²ú¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©¶àÖÐÐÄÏîÄ¿ÐÔÄÜÆÀ¼Û¡±£¨ÏîÄ¿±àºÅ£ºY2021FH-XSYZX04£©¿ÎÌâ  £¬¾­¶àÖÐÐÄʵÑéЧ¹ûÂÛÖ¤£º

£¨1£©¹ú²ú¿¹XaºÍ±ÈÕÕÊÔ¼ÁµÄ²âÖµµÄÏà¹ØÐÔÓÅÒ죺ÎÞÂÛÊÇͨË׸ÎËØÕվɵͷÖ×Ó¸ÎËØ  £¬²âÖµÏà¹ØÐÔ¾ùÔÚR2£¾0.95  £¬¿ÉÖª×ãÁÙ´²¼ì²âÐèÇó£»

£¨2£©¹ú²ú¿¹XaÊÔ¼Á¿ÉÒÔÖª×ãÁÙ´²Ô¤ÆÚÓÃ;£ºÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾¿¹XaÊÔ¼ÁºÐͨË׸ÎËØÏßÐÔ¿ÉÒÔ×öµ½4IU/mL  £¬²»µ«¿ÉÒÔÖª×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL  £¬Í¬Ê±¿ÉÒÔÖª×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÇó£»

£¨3£©¹ú²ú¿¹XaÊÔ¼ÁÐÔÄÜÆÀ¼ÛÓÅÒì  £¬ÎªÁÙ´²Ìṩ¹ú²úÌæ»»µÄÑ¡Ôñ£ºÐÔÄÜÆÀ¼ÛÊý¾ÝÏÔʾ  £¬ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾¿¹XaÊÔ¼ÁºÐµÄ¸÷ÏîÐÔÄÜÓÈÆäÊÇÔÚ¿¹×ÌÈÅÄÜÁ¦·½Ãæ  £¬¶ÔÖ±½Óµ¨ºìËØºÍѪºìÂѰ׵Ŀ¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á¡£



¡¶¿¹Xa¶àÖÐÐÄЧ¹û»ã±¨ÓëÆÊÎö¡·

ԢĿͨµÀ


PC¶ËÊäÈëÏ·½Á´½Ó¼´¿ÉµÇ¼ÄýÑªÔÆ¿ÎÌÃÆ½Ì¨  £¬Ô¢Ä¿ÊÓÆµ£º

https://vfs.xet.tech/s/2YYnDS

H5¶Ëʶ±ðÏ·½¶þάÂë  £¬¼´¿ÉÌø×ªÖÁÊÓÆµÒ³Ã棺




ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾ÑªÄý¼ì²âϵͳ


ÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾ÉúÎïÊÇÖйúÁìÏȵÄÁÙ´²ÌåÍâÕï¶Ï²úÆ·Óë·þÎñ¹©Ó¦ÉÌÖ®Ò»  £¬ÏÖÔÚÓµÓÐ×ÔÖ÷Ñз¢µÄÈ«×Ô¶¯ÄýѪ¼ì²âÆÊÎöÒÇMDC7500ºÍMDC3500ÒÔ¼°µÂ¹úÔ­×°Èë¿ÚµÄCoatron5000¡¢Coatron3000ºÍCoatron1800  £¬×¨ÒµÅäÌ×µÄÄýѪ¼ì²âÊÔ¼ÁÔÚÖª×ã×ÔÓмì²âϵͳµÄͬʱҲÄÜÍêÉÆÆ¥ÅäÖ÷Á÷ѪÄý¼ì²âϵͳ  £¬Öª×ã²î±ð¿Í»§µÄÐèÇó  £¬ÎªÁÙ´²ÌṩÖÜÈ«µÄѪ˨ÓëֹѪʵÑéÊÒ½â¾ö¼Æ»®¡£




²Î¿¼ÎÄÏ×

[1] ÖлªÒ½Ñ§»áÒâѪ¹Ü²¡Ñ§·Ö»á·ÎѪ¹Ü²¡Ñ§×é.¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÖÎÁÆÖйúר¼Ò¹²Ê¶(2015)[J].ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾,2016,44(3):197-211.

[2] ÀµÓîÒ¢,Àî¹ðɺ,ÍõÖ¾Ã÷,µÈ.¿¹Xa»îÐÔ¼ì²âÔÚ¿¹ÄýÒ©Îï¼à²âÖеÄÓ¦ÓÃ[J].±ê¼ÇÃâÒ߯ÊÎöÓëÁÙ´²,2020,27(8):1444-1449.

[3] Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl): e737S-e801S.

[4] ÕźèÑÞ,Èξ²,ÃŽ£Áú.¿¹ÄýÒ©ÎïµÄʵÑéÊÒ¼à²â[J].ÖйúÐÄѪ¹ÜÔÓÖ¾,2019,24(6):565-570.

[5] Vandiver J W , Vondracek T G . Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin[J]. Pharmacotherapy, 2012, 32(6):546-558.

[6] The Extracorporeal Life Support Organization (ELSO).ELSO Anticoagulation Guideline.2014, 1-17.

[7] Babin JL, Traylor KL, Witt DM. Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Semin Thromb Hemost. 2017 Apr;43(3):261-269.

[8] ëøæÂ,ÀîÓÂÄÐ,Â¥ËÉ.¿¹Xa»îÐÔÔÚͨË׸ÎËØ¿¹Äý¼à²âÖÐÓ¦ÓõÄÑо¿Ï£Íû[J].ÖйúÌåÍâÑ­»·ÔÓÖ¾,2018,16(4):248-251.

[9] Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265-72. 

ÉÏÏ»¬¶¯Éó²éÍêÕû²Î¿¼ÎÄÏ×





END

ÎÄÕÂȪԴ£ºÌÚ²©»ãÓÎÏ·¹Ù·½ÍøÕ¾ÉúÎï

Ôð±à£ºEcho

У¶Ô£ºÐ¡¾Å¡¢Pretty



 
ÍøÕ¾µØÍ¼